NASD · Healthcare · Biotechnology · USA
Galectin Therapeutics Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.
Galectin Therapeutics is a clinical-stage biopharmaceutical company developing therapies for fibrotic disease and cancer by targeting galectin proteins using proprietary carbohydrate-based compounds. The company's lead candidate, belapectin, is being studied for treating metabolic dysfunction-associated steatohepatitis with cirrhosis and head and neck cancer. The company pursues drug development programs and seeks strategic partnerships as candidates advance.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Galectin Therapeutics Inc stock.
Not valued: We cannot value this company yet.
10 more funds hold it; the full list is part of the paid plan.
129 more in this industry show a wider margin of safety.
We do not publish a verdict on GALT yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.